Clinical management of drug resistant tuberculosis: A comprehensive review

Sonal Jain¹, Arun Kumar²

¹Medical Writer and Reviewer, ²Associate Professor, Department of Biochemistry, Manipal College of Medical Sciences, Pokhara

ABSTRACT

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. This is because of development of drug resistance in tuberculosis strains, usually called as MDR/XDR-TB. Consequently, novel drugs and regimens for management of these drug resistant TB forms are emerging. Such regimens probably utilize both repurposed drugs and new chemical drugs. This article covers current concepts and recent advances in TB drug discovery and development. An updated review of the mechanisms of action and resistance of the main old and new anti-tuberculosis agents has been described. The consensus statements from RNTCP for management of MDR/XDR-TB have also been discussed.

Key words: Amikacin, Capreomycin, Direct observed therapy-short course, Drug resistance tuberculosis, Isoniazid, Kanamycin, Minimum inhibitory concentration, Multidrug resistance tuberculosis, Open reading frame, Pyrazinamide, Rifampicin, Revised national TB control programme, South east, Extensively drug resistance tuberculosis

TB EPIDEMIOLOGY

Tuberculosis (TB) remains a major health problem and is associated with significant morbidity and mortality.¹ Though a continued decrease in the rate of new TB cases has been reported globally during the last decade, the rate of decline (2% per year) remained slow.¹

1. Global load of disease¹
   - Of the 8.6 million people who developed TB in 2012, 1.1 million (13%) were HIV-positive.
   - Approximately 4, 50,000 people developed MDR-TB and around 1,70,000 deaths from MDR-TB in the year 2012 have been reported.
   - 530,000 TB cases among children <15 years of age and 74,000 TB deaths (among HIV-negative children) have been reported in 2012. This lead to 6% and 8% of the deaths globally, respectively.
   - Most of the cases were in the SE Asia (29%), African (27%) and Western Pacific (19%) regions. India and China alone accounted for 26% and 12% of total cases, respectively in the year 2012.

2. Incidence, Prevalence, Mortality in India²
   - India has more new TB cases annually than any other country. Out of the 9 million TB cases globally, 2.3 million were estimated to have occurred in India in the year 2011 (Table 1).

MULTI-DRUG RESISTANT TB (MDR –TB)

Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to INH and RIF (first line drugs for treatment of TB), with or without resistance to other anti-TB drugs.³

Prevalence of MDR –TB

1. Global Prevalence of MDR-TB⁴
   - Percentage of new and previously treated TB cases that have MDR-TB:
     - Globally, 3.6% of new TB cases and 20.2% of previously treated TB cases are estimated to have MDR-TB.
   - Estimated global incidence of MDR-TB and estimated number of MDR-TB cases among notified TB patients:
Globally, there were an estimated 300,000 MDR-TB cases among notified TB patients in the year 2012.

**HIV and tuberculosis**

Tuberculosis and HIV are the infectious diseases causing the maximum number of deaths globally after malaria.

### 2. Prevalence in India

- In India, MDR-TB among notified pulmonary TB patients has been estimated to be 0.064 millions in the year 2011.

### Classification of Drug resistance TB (DR-TB)

Drug resistance can be categorized into three classes on the basis of the history of previous TB treatment.

1. **Resistance in new patients (previously called ‘primary resistance’)***
   - This type of resistance occurs in the patients with no history of previous TB treatment or patients who have received TB treatment for <1 month previously.

2. **Resistance in previously treated patients (previously called ‘acquired resistance’)***
   - It refers to resistance with one or more previous TB treatment episodes, for >1 month each. Cases of these types are also called as re-treatment cases.

3. **Resistance levels in re-treatment***
   - The re-treatment resistance levels are always higher than resistance in new patients. This provides a measure of the degree to which patients were properly treated.

### Rationale for the Development of Drug-Resistant TB

The basis of resistance to TB drugs is the ability of the *M. tuberculosis* to undergo spontaneous and slow but constant mutations resulting in resistant mutant organisms. This genetic alteration is a naturally occurring phenomenon and varies from drug to drug. The frequency of spontaneous resistance to first-line anti-TB drugs is as follows:

- Isoniazid: 1 in every $10^6$ cell divisions
- Rifampicin: 1 in every $10^6$ cell divisions
- Streptomycin: 1 in every $10^6$ cell divisions
- Ethambutol: 1 in every $10^6$ cell divisions
- Pyrazinamide: 1 in every $10^6$ cell divisions

Erroneous TB treatment with first-line drugs like prescription of inadequate drugs, programme failure with high treatment non-compliance and default can result in the emergence of MDR-TB.

### Risk Factors

The following are special risk factors for MDR tuberculosis:

- Previous anti-tuberculosis therapy
- Immigration from an area with high prevalence of MDR-TB
- Contact with MDR-TB patients
- HIV infection
- Imprisonment

### EXTENSIVELY-DRUG RESISTANT TB (XDR–TB)

Extensively drug resistant TB (XDR-TB) is an uncommon form of tuberculosis, defined as MDR-TB with additional resistance to fluoroquinolones and at least one of the injectable second-line drugs (AMK, CAP or KAN).

### Prevalence of XDR–TB

1. **Global Prevalence of XDR-TB**
   - Globally, 9% of patients with MDR-TB have been reported to have XDR-TB.

2. **Indian Scenario**
   - Recently it has been reported that 3.7% were XDR-TB cases among 483 MDR-TB cases, most of which were previously treated.

### MECHANISMS OF ACTION AND RESISTANCE OF DIFFERENT ANTI–TB DRUGS

Anti-TB drugs are generally categorized into two types: old and new anti-tuberculosis agents. Given below is an updated review of the mechanisms of action and resistance of these drugs so as to provide an insight for proper management strategies for patients suffering from the disease.

### Conventional TB Drugs

1. **Isoniazid(INH)**

   **Mechanism of action**

   Isoniazid (isonicotinic acid hydrazide, INH) is a pro-drug, which involves oxidative activation by KatG (catalase-peroxidase) enzyme of *M. tuberculosis*. The drug acts by inhibiting mycolic acid synthesis pathway of mycobacteria.
The activated form of the drug binds by a covalent linkage to the NADH-dependent enoyl acyl carrier protein (ACP) reductase InhA (a component of the fatty acid synthase II system of mycobacteria), which is crucial for fatty acid elongation.9

**Mechanism of resistance**
Mostly mutations in INH-resistant clinical isolates occurs in KatG gene (in 50–80% of cases), therefore impairing the ability of the catalase-peroxidase to activate the INH pro-drug.9

A single point mutation in KatG gene (substitution of threonine for serine at residue 315 (S315T)) occurs which results in a considerable reduction in catalase and peroxidase activity, and is associated with high-level INH resistance (minimum inhibitory concentration-MIC = 5–10 μg/mL).10

Mutations in InhA may also confer INH resistance. Consequently, there is reduced affinity of the enzyme for NADH without affecting its enoyl reductase activity.11

2. Rifamycins (Rifampicin-RIF)

**Mechanism of action**
Rifamycins act by inhibiting transcription by binding with high affinity to bacterial DNA-dependent RNA polymerase.9

**Mechanism of resistance**
Resistance to RIF occurs mostly as single point mutations in the rpoB gene (encoding the β-subunit of RNA polymerase) with a frequency of 10^{-7} to 10^{-8} organisms.12 90% of RIF-resistant clinical isolates show point mutations cluster in an 81-base pair region between codons 507 and 533 of the rpoB gene (“hot-spot” region). The mutations preponderate in codons 531 [Ser] and 526 [His].13

3. Pyrazinamide (PZA)

**Mechanism of action**
Like INH, PZA also exists in its pro-drug form and requires activation to its active form, pyrazinoic acid (POA), by the action of enzyme pyrazinamidase (PZase).14 It shows anti-tuberculosis activity by disrupting the proton motive force required for essential membrane transport functions by POA at acidic pH.15

**Mechanism of resistance**
PZA resistance occurs mainly due to mutations in the pncA gene encoding PZase. Mutations including point mutations, deletions, and insertions, have been reported in a 561-bp region of the open reading frame (ORF) or in an 82-bp region of its putative promoter.14,16

4. Ethambutol (EMB)

**Mechanism of action**
EMB primarily affects arabinogalactan biosynthesis through inhibition of cell wall arabinan polymerization.17 Besides, EMB has also been reported to inhibit some other cellular pathways like RNA metabolism, mycolic acids transfer into the cell wall, phospholipid synthesis and spermidine biosynthesis.9

**Mechanism of resistance**
Resistance to EMB is mainly due to point mutations in the embCAB operon particularly embB.18

5. Aminoglycosides

**Mechanism of action**
Aminoglycosides are used currently as second-line drugs primarily in the treatment of MDR-TB. Some examples of aminoglycosides having antimycobacterial activity are streptomycin, kanamycin and amikacin. Aminoglycosides acts by inhibiting translation process in mycobacterial species by binding to the 30S ribosomal subunit.9

**Mechanism of resistance**
Mutation of the ribosome target binding sites contributes to resistance to streptomycin and the other aminoglycosides in M. tuberculosis. Approximately 50% of the clinical isolates show mutations in the rpsL gene (encoding the ribosomal protein S12) with the K43R mutation predominating.19 Besides, about 20% of streptomycin-resistant clinical isolates show drug resistance due to mutations in the rrs gene (clustered in the regions adjacent to nucleotides 530 or 912). Recently, it has been shown that mutations in gidB gene (encoding a conserved S-adenosylmethionine-dependent 16S rRNA methyltransferase) also confers low-level resistance to streptomycin.20

6. Fluoroquinolones

The fluoroquinolones are presently used as second-line drugs in TB treatment. This class of anti-TB drugs show exceptional antimycobacterial activity. Some common fluoroquinolones used to treat tuberculosis are moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin, ofloxacin, and ciprofloxacin.

**Mechanism of action**
Fluoroquinolones display their strong antibacterial activity by trapping gyrase and topoisomerase IV on DNA as ternary complexes which results in blockade of the movement of replication forks and transcription complexes.21 Topoisomerase IV is absent in M. tuberculosis, but the genes gyrA and gyrB encoding the A and B subunits of DNA gyrase respectively are present.22
Mechanism of resistance
The main mechanism of fluoroquinolone resistance are the mutations in the conserved quinolone resistance-determining region (QRDR) of gyrA and gyrB which relates between the drug and DNA gyrase. High-level resistance to fluoroquinolones normally occurs when there are multiple mutations in gyrA, or concurrent mutations in gyrA and gyrB. Mutations at positions Ala-90 and Asp-94 in the gyrA gene are most frequent.

7. Macrolides (Clarithromycin)
Mechanism of action
Macrolides exhibit their antibacterial effect by binding to the bacterial 50S ribosomal subunit and inhibiting RNA-dependent protein synthesis.

Mechanism of resistance
Resistance to the macrolides occurs due to low cell wall permeability and expression of the erm(37) gene encoding a 23S rRNA methyltransferase, which is present in all members of the M. tuberculosis complex.

8. Ethionamide
Mechanism of action
Ethionamide occurs in pro-drug form requiring activation by the monoxygenase EthA. Like INH it also inhibits mycolic acid synthesis by binding the ACP reductase InhA.

Mechanism of resistance
Seventy-five percent of M. tuberculosis isolates have mutations in ethA or inhA. Besides, defective mycothiol biosynthesis by M. tuberculosis mshA deletion mutants also contributes to ethionamide resistance probably due to defective activation of the drug.

9. Capreomycin
Mechanism of action
The primary mode of action of capreomycin is inhibition of protein synthesis through modification of ribosomal structures at the 16S rRNA.

Mechanism of resistance
Resistance to capreomycin has been connected with mutations in the rrs gene encoding 16S rRNA.

10. Cycloserine
Mechanism of action
It suspends peptidoglycan synthesis by inhibiting the enzymes d-alanine racemase (AlrA) and d-alanine:d-alanine ligase (Ddl).

Mechanism of resistance
The mechanism by which cycloserine exhibits resistance are not clearly known however it has been reported that overexpression of M. tuberculosis AlrA and Ddl on a multicopy vector results in resistance to D-cycloserine in M. smegmatis and M. bovis BCG.

11. Paraaminosalicylic acid (PAS)

Mechanism of action
PAS is thought to act by inhibiting folic acid biosynthesis and uptake of iron.

Mechanism of resistance
Mutations in the thyA gene encoding the enzyme thimidylate synthesis of the folate biosynthesis pathway confer PAS resistance in M. tuberculosis. Thr202Ala has been found to be common mutation associated with PAS resistance.

Novel TB drugs
A number of novel drugs have emerged recently as potential candidates for the treatment of TB. Their mechanism of action is distinctive from that of the classical anti-TB drugs and thus used to treat MDR–TB.

1. Nitroimidazoles
One of the vital microenvironmental conditions encountered by persistent bacilli within necrotic lung granulomas in the human host is reduced oxygen tension. As a result, the bacilli become susceptible to metronidazole a nitroimidazole drug used to treat anaerobic infections. Metronidazole, requires activation by the pyruvate: ferredoxin oxidoreductase system under anoxic conditions. Examples of nitroimidazoles which show antimycobacterial activity are PA-824 and OPC-67683.

PA-824
Mechanism of action
PA-824 has been shown to display bactericidal activity against actively multiplying and non-replicating bacilli. It is a pro-drug requiring reductive activation of an aromatic nitro group to exhibit its antitubercular activity. This requires an F420-dependent glucose-6-phosphate dehydrogenase encoded by Rv0407 (fgd1) and deazaflavin-dependent nitroreductase (Ddn) encoded by Rv3547. The bactericidal activity of PA-824 is attributed to the formation of the des-nitroimidazole metabolite of PA-824 which is considered to generate reactive nitrogen species like nitric oxide.

OPC-67683 (Delamanid)
Mechanism of action
OPC-67683 is a pro-drug requiring reductive activation by M. tuberculosis. The drug inhibits the synthesis of methoxy- and keto-mycolic acids.
Mechanism of resistance
Similar to that of PA-824, defective activation of the drug due to mutations in the Rv3547 gene is the basis of resistance of OPC-67683.39

2. TMC207 (Bedaquiline)
Mechanism of action
TMC207 ([R207910 or “J compound”]) is a first-in-class anti-TB diarylquinoline which show bactericidal and sterilizing activities against drug-susceptible and drug-resistant M. tuberculosis in vitro and in animal models. TMC207 acts by inhibiting a principal enzyme ATP synthase required for synthesis of ATP for M. tuberculosis40,41

Mechanism of resistance
Resistance to TMC207 is considered due to mutations in the atpE gene encoding the transmembrane and oligomeric C subunit of ATP synthase42 though more recent studies have reported that maximum number of mutants resistant to TMC207 lacked mutations in atpE. This indicates the existence of alternative drug resistance mechanisms.9

3. Oxazolidinones
Oxazolidinones are a new chemical class of synthetic antibiotics which act by inhibiting of protein synthesis. Examples of oxazolidinones which show antitubercular activity are linezolid, PNU-100480 and AZD5847.9

Linezolid
Mechanism of action
Linezolid is the first compound belonging to the oxazolidinone class generally used to treat drug resistant TB. It is active against intracellular bacilli and acts by binding to the ribosomal 50S subunit and thus inhibiting an early step in protein synthesis.43

Mechanism of resistance
Mutations at G2061T and G2576T in the 23S rRNA gene have been reported in in vitro-selected mutants which showed high resistance to linezolid (MIC = 16–32 mg/L).44

PNU-100480
PNU-100480 is another effective oxazolidinone having MIC of PNU100480 half that of linezolid. Studies have demonstrated that combination of PNU-100480 to the standard first-line regimen of rifampin, INH, and PZA can decrease the duration of treatment necessary to prevent relapse.45

AZD5847
AZD5847 shows its bactericidal activity against M. tuberculosis in macrophages. Recent phase I trials have shown that oral administration of the drug up to 800 mg bid for 14 days was well tolerated in healthy volunteers. Though bioavailability decreases with increasing dose but this effect can be considerably reduced if taken within 2 hours of meals, and the exposures achieved in man correspond to efficacious exposures in the mouse model of TB infection.46

4. Ngeranyl-N’-(2-adamantyl)ethane-1,2-diamine (SQ109)
SQ109, a novel drug has been found to be an effective treatment for TB together with MDR-TB. The clinical studies show the drug’s ability to augment the treatment of TB during the first 2 months of intensive therapy and also to treat MDR-TB.47 Whether upregulation of ahpC expression plays role for resistance to SQ109 is yet to be determined.48

5. Phenothiazines
One of the classical example of the phenothiazine drug which has been reported to have bactericidal activity against drug-susceptible and drug-resistant M. tuberculosis in macrophages is the antipsychotic drug thioridazine.49 Thioridazine has been shown to effectively cure patients with XDR-TB in Argentina and as salvage therapy in similar patients in India.50 The mode of action of thioridazine together with inhibition of type II NADH:menaquinone oxidoreductase as a phenothiazine involves its effect on enzymes of fatty acid metabolism and membrane proteins, particularly efflux pumps.51,52

6. Benzothiazinones (BTZs)
The 1,3-benzothiazin-4-ones (BTZs) are a new class of drugs showing activity against M. tuberculosis in vitro, ex vivo, and in murine TB models.9 BTZs act by inhibiting the enzymatic activity of decaprenylphosphoryl-β-D-ribose 2’-epimerase (DprE1) enzyme thus eliminating the formation of decaprenylphosphoryl arabinose, a key precursor required for the synthesis of the cell-wall arabinans, thus causing bacterial lysis and death.53

Management strategies for MDR/XDR-TB
Treatment of MDR-TB and XDR-TB is more complicated than that of susceptible TB. For treatment of MDR-TB and XDR-TB second-line drugs which are less efficient are usually required because first line drugs like isoniazid and rifampin cannot be used. Because of less potency of second line drugs more quantity of them are needed for a long durations.54 Table 2 gives the list of the drugs used to treat MDR-TB.

The most common principles used to treat MDR-TB are as follows:
1. Treatment by any first line agent to which susceptibility has been reported.3
2. Introduce an injectable drug for a minimum of 6 months of negative cultures.55
3. Treatment by fluoroquinolone whenever possible.35
4. Addition of other second-line agents to reach a minimum of four or five drugs.35
5. In the case of severe parenchymal damage, high-grade resistance or clinically advanced stages, use of strengthening agents with in vitro evidence of antimycobacterial activity.35

**Consensus statement for management of MDR-TB**

Revised National Tuberculosis Control Programme (RNTCP) has developed national guidelines for scaling up management of MDR-TB. All health care providers (both in public and private sector) need to adhere to the following for the management of MDR-TB:

1. MDR-TB management should be done only at selected health institutions having required experienced medical expertise and availability of diagnostic and treatment facilities.36

2. **Diagnosis of MDR-TB**36
   - On the basis of history of previous treatment (e.g. smear positive case after repeated treatment courses etc.) and/or close contact to a possible source case confirmatory of having drug-resistant TB
   - Diagnosis of MDR-TB should be done in drug resistance suspected cases through culture and drug susceptibility testing (DST) from a quality-assured laboratory.

3. **Analysis of DST results**36
   - Due to the poor reproducibility, DST results of the 1st line anti-TB drugs pyrazinamide, streptomycin, and ethambutol should be interpreted with care even under optimal laboratory conditions.
   - Due to absence of quality-assurance, and lack of standardized methodology DST results of 2nd line anti-TB drugs (fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, sparfloxacin, pefloxacin); kanamycin, amikacin, capreomycin, ethionamide, prothionamide, cycloserine and PAS should be interpreted with great care.

4. **Treatment regimen**36
   - All significant examination to be performed prior to treatment initiation.
   - The standardized regimen as recommended in the national Directly Observed Treatment, Short Course (DOTS)-Plus guidelines should be used [6(9) Km Ofx Eto Cs Z E/18 Ofx Eto Cs E]
   - For patients in whom the results of 2nd line DST from a recognized laboratory are available, an individualized regimen may be used after obtaining a detailed history of previous anti-TB treatment

5. **Treatment Duration**36
   - At least six months of Intensive Phase (IP) should be given which is extended up to 9 months for those who have a positive culture result taken at 4th month of treatment.
   - Continuation Phase (CP) should be given for at least 18 months of following the Intensive Phase.

6. **Follow-up schedule**36
   - Every month smear examination during IP and at least quarterly during CP
   - Culture examination should be done at least at 4, 6, 12, 18 and 24 months of treatment
   - Other important examinations should be done.

7. **Treatment adherence and support**36
   - Intensive counselling of all patients and their family members prior to and during treatment and all follow-up visits
   - To minimize the risk of development of resistance to second-line anti-TB drugs and attain optimal treatment outcomes, administration of treatment under direct observation (DOT) over the entire course of treatment
   - If there is unfeasibility of DOT, efforts to ensure treatment adherence should be made by

---

6(9) = 6-9 months; Km = Kanamycin; Ofx = Ofloxacin; Eto = Ethionamide; Cs = Cycloserine; Z = Pyrazinamide; E = Ethambutol
They are testing resistant may be affected.

Options with XDR-TB are very limited and some strains good, there are little data on clinical efficacy of the test. Reproducibility and reliability of DST to injectables are.

High-dose isoniazid treatment should be given if low-level resistance is reported.

Use two or more agents from Group 5.

High-dose isoniazid treatment should be given if low-level resistance is reported.

Adjunct surgery can be taken if there is localized disease.

This recommendation is made because, while the reproducibility and reliability of DST to injectables are good, there are little data on clinical efficacy of the test. Options with XDR-TB are very limited and some strains may be affected in vivo by an injectable agent even though they are testing resistant in vitro.

Treat HIV.

Provide comprehensive monitoring and full adherence support.

Consensus statement for XDR-TB

The principles used for treatment of XDR-TB are same to those used for the treatment of MDR-TB, with oral agents prescribed for at least 18 months and injectable drugs prescribed for at least 8 months beyond culture conversion. The latest expert consensus to manage XDR-TB is given below:

1. Use any Group 1 agents that may be efficient.
2. Use an injectable agent to which strain is susceptible and consider an extended duration of use (12 months or possibly the whole treatment). In case of resistance to all injectable agents, use one that has never administered before.
3. Use a later-generation fluoroquinolone such as moxifloxacin.
4. Use all Group 4 agents that have not been used extensively in a previous regimen or any that are likely to be effective.
5. Use two or more agents from Group 5.
6. High-dose isoniazid treatment should be given if low-level resistance is reported.
7. Adjunct surgery can be taken if there is localized disease.
8. Make sure of strong infection control measures.
9. Treat HIV.
10. Provide comprehensive monitoring and full adherence support.

Key recommendations from WHO guidelines for the programmatic management of DR-TB

- At least four second-line antituberculosis drugs likely to be effective as well as pyrazinamide during IP of treatment.
- Use only four second-line anti-tuberculosis drugs in patients with extensive disease (do not add more drugs). Number of second-line drugs can be increased in a regimen if the effectiveness of some of the drugs is uncertain permitted.
- The regimen should include pyrazinamide, a fluoroquinolone, a parenteral agent, ethionamide (or prothionamide) and cycloserine, or PAS if cycloserine cannot be used.
- Ethambutol may be used but is not included among the drugs making up the standard regimen.
- Group 5 drugs may be used but are not included among the drugs making up the standard regimen.
- Do not use ciprofloxacin as an antituberculosis agent.

REFERENCES

Jain and Kumar: Clinical management of drug resistant tuberculosis


Authors Contribution:
SJ – Drafted the manuscript, Referencing and reviewing the manuscript; AK – Manuscript preparation, reviewing the manuscript, Final editing of the manuscript.

Source of Support: Nil, Conflict of Interest: None declared.